A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/436 (2006.01) A61K 31/519 (2006.01) A61K 45/06 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2743242
The present invention provides a combination therapy comprising the compound 4- [4-[4-(4-fluoro-3-trifluo- romethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4- d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an mTOR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small- cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, mammary carcinoma, renal cell carcimoma, multiple myeloma, Kaposis Sarcoma, Hodgkins lymphoma, lymphangioleiomyomatosis, Non-Hodgkins lymphoma or sarcoma.
La présente invention concerne une thérapie combinée comprenant le composé 4-[4-[4-(4-fluoro-3-trifluorométhyl-phényl)-1-méthyl-1H-imidazol-2-yl]-pipéridine-1-yl]-1H-pyrazolo[3,4-d]pyrimidine ou l'un de ses sels pharmaceutiquement admis, et un inhibiteur de mTOR. Ce composé convient au traitement du glioblastome multiforme, de l'adénocarcinome du colon, du cancer du poumon non à petites cellules, du cancer du poumon à petites cellules, du cancer du poumon à petites cellules résistant au cisplatine, du cancer des ovaires, de la leucémie, du cancer du pancréas, du cancer de la prostate, du carcinome mammaire, de l'hypernéphrome, du myélome multiple, du sarcome de Kaposi, du lymphome de Hodgkin, de la lymphangioléiomyomatose, et du lymphome ou du sarcome non de Hodgkin.
Donoho Gregory Paul
Geeganage Sandaruwan
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
P70 s6 kinase inhibitor and mtor inhibitor combination therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P70 s6 kinase inhibitor and mtor inhibitor combination therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P70 s6 kinase inhibitor and mtor inhibitor combination therapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1557266